Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur B Epstein

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Optometry (St. Louis, Mo.)|December 18, 2003
Ocular allergyArthur B Epstein
Eye & Contact Lens|May 17, 2006
Contact lens care products effect on corneal sensitivity and patient comfortArthur B Epstein
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
In the aftermath of the Fusarium keratitis outbreak: What have we learned?Arthur B Epstein
Clinical Therapeutics|July 16, 2002
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge modelGregg J Berdy, Juan O Stoppel, Arthur B Epstein
Clinical Therapeutics|December 13, 2006
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge studyIra Finegold, David B Granet, Peter A D'Arienzo, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studiesArthur B Epstein, Peter T Van Hoven, Alan Kaufman, et al.
Eye & Contact Lens|April 16, 2003
Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge modelMiguel Brodsky, William E Berger, Salim Butrus, et al.
Eye & Contact Lens|May 30, 2003
The case for continuous wearArthur B Epstein, Henry D Perry, Joseph M Freedman, et al.
Current Eye Research|December 19, 2007
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challengeMark B Abelson, Dennis L Spangler, Arthur B Epstein, et al.
Current Medical Research and Opinion|August 25, 2004
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge modelBobby Q Lanier, Ira Finegold, Peter D'Arienzo, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Optometry (St. Louis, Mo.)|December 18, 2003
Ocular allergyArthur B Epstein
Eye & Contact Lens|May 17, 2006
Contact lens care products effect on corneal sensitivity and patient comfortArthur B Epstein
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
In the aftermath of the Fusarium keratitis outbreak: What have we learned?Arthur B Epstein
Clinical Therapeutics|July 16, 2002
Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge modelGregg J Berdy, Juan O Stoppel, Arthur B Epstein
Clinical Therapeutics|December 13, 2006
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge studyIra Finegold, David B Granet, Peter A D'Arienzo, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 12, 2009
Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studiesArthur B Epstein, Peter T Van Hoven, Alan Kaufman, et al.
Eye & Contact Lens|April 16, 2003
Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge modelMiguel Brodsky, William E Berger, Salim Butrus, et al.
Eye & Contact Lens|May 30, 2003
The case for continuous wearArthur B Epstein, Henry D Perry, Joseph M Freedman, et al.
Current Eye Research|December 19, 2007
Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challengeMark B Abelson, Dennis L Spangler, Arthur B Epstein, et al.
Current Medical Research and Opinion|August 25, 2004
Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge modelBobby Q Lanier, Ira Finegold, Peter D'Arienzo, et al.
Pageof 2